Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-Term Pre-Eclampsia Cases

Published: Thursday, July 12, 2012
Last Updated: Tuesday, July 17, 2012
Bookmark and Share
The test correctly identifies 80% of women at risk for the development of pre-term pre-eclampsia according to a study in collaboration with the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium.

Pronota NV announces that it has successfully validated its mid-gestation pre-eclampsia screening test.

Pre-eclampsia is responsible for 50,000 maternal deaths annually and is a major cause of premature and still births. This potentially devastating condition is unique to pregnancy and primarily affects women who are pregnant for the first time. Between 4 and 7% of healthy women have their first pregnancy complicated with pre-eclampsia with no prior predisposition or warning signs. Pronota’s assay, which combines five protein biomarkers and blood pressure, offers an improvement to existing tests.

Dr. Philip Baker, Professor of Obstetrics and Gynaecology at the University of Alberta, commented: “A test that correctly identifies women at risk of pre-eclampsia could allow physicians to adapt prenatal care and lead to improved outcomes for both mothers and infants.”

Pronota used its proprietary proteomics platforms to identify, verify and validate a panel of novel blood biomarkers which are predictive of pre-eclampsia at the mid-gestation time point. An unbiased large scale proteomics biomarker discovery experiment was followed by verification of the results in 300 women who either subsequently developed pre-eclampsia or did not. The predictive merit of the biomarker panel was subsequently confirmed in another study of 300 women from a different population. In this validation study, the screening test identified 80% of the women who developed pre-eclampsia that resulted in birth of a premature baby (preterm pre-eclampsia). These MS based results were successfully translated to an ELISA type read out. This important milestone was achieved through a longstanding scientific collaboration with Professor Baker from the University of Alberta, Professor North from King’s College, London and Dr. Myers from Manchester Maternal & Fetal Health Research Centre, UK.

Professor North from King’s College, London, commented: “The prediction model developed in this study represents a rare example of a rigorously validated proteomic biomarker study, the findings of which have the potential to be translated into a clinical prediction tool.”

The cohort used for the study was compiled by the SCOPE Consortium who collected blood samples and gathered medical and lifestyle information from 5,600 women in six centres across Australia, New Zealand, the UK and the Republic of Ireland over eight years. This controlled prospective study using high quality plasma samples and clinical data allowed for the rigorous and stepwise validation of Pronota’s test.

Dr. Jenny Myers, Clinical Senior Lecturer, Manchester Maternal & Fetal Health Research Centre, UK, will present a discussion of the Pronota-SCOPE study at the International Society for the Study of Hypertension in Pregnancy meeting in Geneva in July.

Katleen Verleysen, CEO of Pronota, said: “We are very pleased to bring forward a novel combination of biomarkers predictive for pre-eclampsia, which will provide physicians with the best tools to ensure the highest quality of care for patients. This study also validates Pronota’s approach towards biomarker discovery and validation, a company capable of taking unbiased discovery results through to validation.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pronota is to Receive Patent on Biomarker for Diagnosing Renal Failure
USPTO has allowed Company’s patent for the use of a blood-based biomarker LG3.
Friday, June 07, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!